175 related articles for article (PubMed ID: 37450093)
1. A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
Kobayashi S; Ikeda M; Nakachi K; Ueno M; Okusaka T; Todaka A; Satoi S; Tomokuni A; Konishi M; Furuse J
Ann Surg Oncol; 2023 Nov; 30(12):7331-7337. PubMed ID: 37450093
[TBL] [Abstract][Full Text] [Related]
2. Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone.
Kagoura M; Kobayashi S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N
Eur J Surg Oncol; 2024 Mar; 50(3):107980. PubMed ID: 38281442
[TBL] [Abstract][Full Text] [Related]
3. Correction: A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
Kobayashi S; Ikeda M; Nakachi K; Ueno M; Okusaka T; Todaka A; Satoi S; Tomokuni A; Konishi M; Furuse J
Ann Surg Oncol; 2023 Oct; 30(11):6651. PubMed ID: 37505358
[No Abstract] [Full Text] [Related]
4. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).
Nakachi K; Konishi M; Ikeda M; Mizusawa J; Eba J; Okusaka T; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2018 Apr; 48(4):392-395. PubMed ID: 29462482
[TBL] [Abstract][Full Text] [Related]
5. Current progress in perioperative chemotherapy for biliary tract cancer.
Ioka T; Shindo Y; Ueno M; Nagano H
Ann Gastroenterol Surg; 2023 Jul; 7(4):565-571. PubMed ID: 37416744
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.
Kobayashi S; Nakachi K; Ikeda M; Konishi M; Ogawa G; Sugiura T; Yanagimoto H; Morinaga S; Wada H; Shimada K; Takahashi Y; Nakagohri T; Kamata K; Shimizu Y; Ajiki T; Hirano S; Gotohda N; Ueno M; Okusaka T; Furuse J
Eur J Surg Oncol; 2024 Feb; 50(2):107324. PubMed ID: 38157649
[TBL] [Abstract][Full Text] [Related]
7. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Itano O; Takemura Y; Kishida N; Tamagawa E; Shinozaki H; Ikeda K; Urakami H; Ei S; Hayatsu S; Suzuki K; Sakuragawa T; Ishii M; Shito M; Aiura K; Fujisaki H; Takano K; Matsui J; Minagawa T; Shinoda M; Kitago M; Abe Y; Yagi H; Oshima G; Hori S; Kitagawa Y
BMC Cancer; 2020 Jul; 20(1):688. PubMed ID: 32703191
[TBL] [Abstract][Full Text] [Related]
8. Completion of adjuvant S-1 chemotherapy after surgical resection for biliary tract cancer: A single center experience.
Iwaki K; Yoh T; Nishino H; Nishio T; Koyama Y; Ogiso S; Ishii T; Kanai M; Hatano E
Asian J Surg; 2024 Mar; 47(3):1383-1388. PubMed ID: 38160154
[TBL] [Abstract][Full Text] [Related]
9. Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan.
Yoh K; Takamochi K; Shukuya T; Hishida T; Tsuboi M; Sakurai H; Goto Y; Yoshida K; Ohde Y; Okumura S; Ohashi Y; Kunitoh H
Jpn J Clin Oncol; 2019 Jan; 49(1):63-68. PubMed ID: 30452719
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
Nakachi K; Konishi M; Ikeda M; Shimada K; Okusaka T; Saiura A; Ishii H; Sugiyama M; Furuse J; Sakamoto H; Shimamura T; Ohta T
Int J Clin Oncol; 2018 Oct; 23(5):894-899. PubMed ID: 29705976
[TBL] [Abstract][Full Text] [Related]
11. Understanding Barriers to Enrollment in Adjuvant Clinical Trials: Insights into Patient Eligibility Criteria from the Adjuvant S-1 for Cholangiocarcinoma Trial (JCOG1202, ASCOT).
Sood D; Mayo SC
Ann Surg Oncol; 2023 Nov; 30(12):6967-6969. PubMed ID: 37684366
[No Abstract] [Full Text] [Related]
12. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
Rizzo A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
14. Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers.
Rhodin KE; Liu A; Bartholomew A; Kramer R; Parameswaran A; Uronis H; Strickler J; Hsu D; Morse MA; Shah KN; Herbert G; Zani S; Nussbaum DP; Allen PJ; Lidsky ME
Ann Surg Oncol; 2023 Aug; 30(8):4813-4821. PubMed ID: 37188803
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
Song S; Yang W; Tian H; Gong S; Lei C; Lv K; Lu T; Cheng Q; Yang K; Guo T
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101788. PubMed ID: 34389530
[TBL] [Abstract][Full Text] [Related]
16. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review.
Yoo C; Shin SH; Park JO; Kim KP; Jeong JH; Ryoo BY; Lee W; Song KB; Hwang DW; Park JH; Lee JH
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916008
[TBL] [Abstract][Full Text] [Related]
17. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.
Rizzo A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):547-554. PubMed ID: 33571059
[No Abstract] [Full Text] [Related]
18. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
Seita K; Ebata T; Mizuno T; Maeda A; Yamaguchi R; Kurumiya Y; Sakamoto E; Hiramatsu K; Ando M; Nagino M
Ann Surg Oncol; 2020 Jul; 27(7):2348-2356. PubMed ID: 32180066
[TBL] [Abstract][Full Text] [Related]
20. DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study.
Woo SM; Yoon KA; Hong EK; Park WS; Han SS; Park SJ; Joo J; Park EY; Lee JH; Kim YH; Kim TH; Lee WJ
Oncotarget; 2017 Oct; 8(46):81394-81404. PubMed ID: 29113399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
